LAUSR

Background: The pandemic influenza A (H1N1) virus has spread worldwide and infected a large proportion of the human population. Discovery of new and effective drugs for the treatment of influenza is a crucial issue for the global medical community. According to our previous study, TSL‐1, a fraction of the aqueous extract from the tender leaf of Toonasinensis, has demonstrated antiviral activities against pandemic influenza A (H1N1) through the down‐regulation of adhesion molecules and chemokine to prevent viral attachment. Methods: The aim of the present study was to identify the active compounds in TSL‐1 which exert anti‐influenza A (H1N1) virus effects. XTT assay was used to detect the cell viability. Meanwhile, the inhibitory effect on the pandemic influenza A (H1N1) virus was analyzed by observing plaque formation, qRT‐PCR, neuraminidase activity, and immunofluorescence staining of influenza A‐specific glycoprotein. Results: Both catechin and gallic acid were found to be potent inhibitors in terms of influenza virus mRNA replication and MDCK plaque formation. Additionally, both compounds inhibited neuraminidase activities and viral glycoprotein. The 50% effective inhibition concentration (EC50) of catechin and gallic acid for the influenza A (H1N1) virus were 18.4 &mgr;g/mL and 2.6 &mgr;g/mL, respectively; whereas the 50% cytotoxic concentrations (CC50) of catechin and gallic acid were >100 &mgr;g/mL and 22.1 &mgr;g/mL, respectively. Thus, the selectivity indexes (SI) of catechin and gallic acid were >5.6 and 22.1, respectively. Conclusion: The present study demonstrates that catechin might be a safe reagent for long‐term use to prevent influenza A (H1N1) virus infection; whereas gallic acid might be a sensitive reagent to inhibit influenza virus infection. We conclude that these two phyto‐chemicals in TSL‐1 are responsible for exerting anti‐pandemic influenza A (H1N1) virus effects.